OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Spring on the Rationale for the AMEERA-1 Trial in ER+/HER2- Advanced Breast Cancer

February 1st 2022

Laura Spring, MD, discusses the rationale for the ongoing phase 1/2 AMEERA-1 trial in estrogen receptor–positive, HER2-negative advanced breast cancer.

Women in Oncology: Early Experiences as a Female Oncologist

February 1st 2022

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss their early experiences as female oncologists and some of the gender-related challenges they faced during their careers.

Dr. Olawaiye on Investigating Balstilimab Plus Zalifrelimab in Gynecologic Cancers

February 1st 2022

Alexander Babatunde Olawaiye, MD, discusses the investigation of balstilimab plus zalifrelimab in gynecologic cancers.

Dr. Krop on Evaluating De-Escalated Treatment Strategies in HER2+ Breast Cancer

January 31st 2022

Ian E. Krop, MD, PhD, discusses the need to evaluate de-escalated treatment strategies in HER2-positive breast cancer.

Dr. Hurvitz on Progress Made With Antibody-Drug Conjugates in HER2+ Breast Cancer

January 31st 2022

Sara A. Hurvitz, MD, discusses progress made in 2021 with antibody-drug conjugates in HER2-positive breast cancer.

Dr. Rao on Incorporating Updated NCCN Guidelines Into Treatment Selection for HER2+ Breast Cancer

January 31st 2022

Ruta D. Rao, MD, discusses how the updated National Comprehensive Cancer Network guidelines have influenced treatment selection for patients with HER2-positive breast cancer.

Dr. Eakin on Racial Disparities in Uterine Cancer

January 31st 2022

Cortney Eakin, MD, discusses racial disparities and histology trends in uterine cancer.

Dr. Cosgrove on Utilizing Biomarker-Informed Treatments Endometrial Cancer

January 31st 2022

Casey M. Cosgrove, MD, discusses utilizing biomarker-informed treatments in endometrial cancer.

Fellows on Film: What Makes a Good Mentor for an Oncology Fellow?

January 31st 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the qualities that make someone a great mentor for an oncology fellow.

Fellows on Film: How Do Fellowship Directors Select Applicants?

January 31st 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the process of selecting applicants to be accepted into an oncology fellowship.

Fellows on Film: Is the General Oncologist Still a Possibility?

January 31st 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss whether it's still a possibility to be a general oncologist following an oncology fellowship.

Fellows on Film: The Compact Style of Oncology Fellowship Training

January 31st 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the compact style that comprises oncology fellowship training.

Fellows on Film: Selecting a Mentor During Oncology Fellowship

January 31st 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, share advice in selecting a mentor during an oncology fellowship.

Dr. Kato on the Characterization of BRAF Mutations in Oncology

January 31st 2022

Shumei Kato, MD, discusses the characterization of BRAF mutations in oncology.

Dr. Lee on the Association of MSI-H, dMMR, and TMB-H Features in Endometrial Cancer

January 28th 2022

Sarah Lee, MD, MBA, discusses the association of microsatellite instability–high, mismatch repair deficiency, and tumor mutational burden–high features in endometrial cancer.

Dr. Karam on the Role of Debulking Surgery in Recurrent Ovarian Cancer

January 28th 2022

Amer Karam, MD, discusses determining whether to use debulking surgery after recurrence in ovarian cancer.

Fellows on Film: Lessons Learned During Oncology Fellowship

January 28th 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, share their experiences as a fellowship director and an oncology fellow, respectively.

Dr. Casablanca on the Integration of Pembrolizumab in Recurrent or Metastatic Cervical Cancer

January 28th 2022

Yovanni Casablanca, MD, discusses the integration of pembrolizumab (Keytruda) into the paradigm of recurrent or metastatic cervical cancer.

Dr. Chandra on the Need for Resources to Evaluate Racial Disparities in Prostate Cancer

January 28th 2022

Dhyan Chandra, PhD, discusses the need for resources to evaluate racial disparities in prostate cancer.

Dr. Verstovsek on the Tolerability of Momelotinib in Myelofibrosis

January 28th 2022

Srdan Verstovsek, MD, PhD, discusses the tolerability of momelotinib in myelofibrosis.